Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Convertible Debt (2016 - 2024)

Historic Convertible Debt for Regen BioPharma (RGBP) over the last 9 years, with Q2 2024 value amounting to $499880.0.

  • Regen BioPharma's Convertible Debt changed 0.0% to $499880.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $499880.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $499880.0 for FY2023, which is 6040.05% down from last year.
  • Regen BioPharma's Convertible Debt amounted to $499880.0 in Q2 2024, which was down 0.0% from $499880.0 recorded in Q1 2024.
  • Regen BioPharma's 5-year Convertible Debt high stood at $3.0 million for Q1 2022, and its period low was $499880.0 during Q4 2022.
  • Its 5-year average for Convertible Debt is $1.5 million, with a median of $1.4 million in 2022.
  • In the last 5 years, Regen BioPharma's Convertible Debt soared by 16046.39% in 2020 and then tumbled by 8326.63% in 2023.
  • Quarter analysis of 5 years shows Regen BioPharma's Convertible Debt stood at $2.5 million in 2020, then tumbled by 49.58% to $1.3 million in 2021, then plummeted by 60.4% to $499880.0 in 2022, then changed by 0.0% to $499880.0 in 2023, then changed by 0.0% to $499880.0 in 2024.
  • Its Convertible Debt stands at $499880.0 for Q2 2024, versus $499880.0 for Q1 2024 and $499880.0 for Q4 2023.